By Elizabeth Sweeney, Project Manager
As part of the 4th Annual Asia Scientific Congress held in Shanghai, China, the National Comprehensive Cancer Network® (NCCN®) convened the NCCN Hematologic Malignancies Congress on April 10, 2011. The collaborative Congress presented to more than 75 Chinese hematologists and aimed to further the treatment of hematologic malignancies in China.
Sessions from the Congress included opening remarks from Professor Zhixiang Shen and presentations on chronic myelogenous leukemia (CML), multiple myeloma (MM), and myelodysplastic syndromes (MDS). Presenting NCCN Guidelines Panel Members included Dr. Jerald P. Radich, of Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Dr. Seema Singhal, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Focusing on the data from which the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Chronic Myelogenous Leukemia were derived, Dr. Radich's presentations on CML concentrated on the 2nd generation drugs, dasatinib and nilotinib, versus the 1st generation drug, imatinib. He also highlighted how to select a front-line therapy, how to tailor therapy by predicting response and failure, and whether complete molecular response is necessary.
Dr. Radich and Dr. Singhal also presented sessions on MM and MDS to an audience of 20 of the top hematologists in China. During these presentations, a consensus discussion resulted in minor adjustments to be made to the NCCN Guidelines, China Editions for Multiple Myeloma.
As China does not have access to the same drugs listed in the NCCN Guidelines™, an ongoing focus of the Congress involves adapting the information in the NCCN Guidelines to the Chinese demographic. Consequently, NCCN and Chinese hematologists will continue working together to reduce the gaps in treatment of hematologic malignancies that exist in China.